After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.67 and fluctuated between $1.7400 as its day high and $1.5700 as its day low. The current market capitalization of Clearside Biomedical Inc is $124.78M. A total of 2.98 million shares were traded on the day, compared to an average of 216.10K shares.
In the most recent transaction, WHITMORE BRADFORD T bought 444,444 shares of CLSD for 1.35 per share on Feb 07 ’24. After the transaction, the 10% Owner now owns 4,495,034 company shares. In a previous transaction on Jan 19 ’24, LASEZKAY GEORGE M sold 18,000 shares at 1.27 per share. CLSD shares that CEO owns now total 466,577.
Among the insiders who sold shares, Deignan Charles A. disposed of 12,900 shares on Jan 19 ’24 at a per-share price of $1.28. This resulted in the Chief Financial Officer holding 384,662 shares of CLSD after the transaction. In another insider transaction, WHITMORE BRADFORD T bought 64,366 shares at $0.74 per share on Nov 01 ’23. Company shares held by the 10% Owner now total 4,050,590.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, CLSD has a high of $1.65 and a low of $0.65.
As of this writing, CLSD has an earnings estimate of -$0.09 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$0.15. The company reported an EPS of -$0.15 in the last quarter, which was -7.10% lower than expectations of -$0.14.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CLSD’s latest balance sheet shows that the firm has $30.44M in Cash & Short Term Investments as of fiscal 2021. There were $675.00k in debt and $4.64M in liabilities at the time. Its Book Value Per Share was -$0.21, while its Total Shareholder’s Equity was $37.98M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLSD is Buy with a score of 4.80.
